Harbor Investment Advisory LLC Cuts Position in Moderna, Inc. (NASDAQ:MRNA)

Harbor Investment Advisory LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA) by 69.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 800 shares of the company’s stock after selling 1,843 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Moderna were worth $33,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Blue Trust Inc. raised its holdings in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the period. Larson Financial Group LLC raised its holdings in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. Rakuten Securities Inc. raised its holdings in shares of Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Finally, Brooklyn Investment Group purchased a new position in shares of Moderna in the 3rd quarter worth about $80,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 2,664 shares of company stock worth $115,210 in the last 90 days. 15.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research reports. Leerink Partners cut their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Bank of America reiterated an “underperform” rating and set a $41.00 target price on shares of Moderna in a report on Tuesday, December 10th. Barclays dropped their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Four analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus price target of $75.58.

Moderna Price Performance

Shares of MRNA opened at $38.50 on Thursday. The firm has a market cap of $14.82 billion, a price-to-earnings ratio of -6.62 and a beta of 1.60. The stock has a 50 day moving average of $40.52 and a 200-day moving average of $64.90. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.39) EPS. As a group, analysts forecast that Moderna, Inc. will post -9.27 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.